Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease

Journal of Neurology, Supplement

Volumn 247, Issue 2, 2000, Pages 11-18

  Brooks, David J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; MRI; MRS; Parkinson's disease; PET; SPECT

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; IODINE 123; N ACETYLASPARTIC ACID;

CONFERENCE PAPER; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034090878     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Baron JC, Maziere B, Loc'h C, Cambon H, Sgouropoulos P, Bonnet M, Agid Y (1986) Loss of striatal (76Br)bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 6: 131-136
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological, and neurochemical correlations. J Neurol Sci 20: 415-455
3. Blin J, Baron JC, Dubois P, Pillon B, Cambon H, Cambier J, Agid Y (1990) Positron emission tomography study in progressive supranuclear palsy. Arch Neurol 47:747-752
4. 11C-raclopride and PET. Ann Neurol 31:184-192
5. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 28:547-555
6. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RSJ (1990) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system, in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 113: 1539-1552
7. Brucke T, Asenbaum S, Pirker W, Pozzera A, Wenger S, Wober C, Muller C, Angelberger P, Podreka I (1995) Quantification of dopaminergic nerve cell loss in Parkinson's disease with [I-123]-β-CIT. J Cereb Blood Flow Metab 15 (Supp 1):S37
8. Burn DJ, Sawle GV, Brooks DJ (1994) The differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 57: 278-284
9. Davie CA, Barker GJ, Machado C, Miller DH, Lees AJ (1997) Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 12: 767-771
10. Davie CA, Wenning GK, Barker GJ, Tofts PS, Phil D, Kendall BE, Quinn N, McDonald WI, Marsden CD, Miller DH (1995) Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 37:204-210
11. De Voider AG, Francard J, Laterre C, Dooms G, Bol A, Michel C, Goffinet AM (1989) Decreased glucose utilisation in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 26: 239-247
12. Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer S (1986) Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 159:493-498
13. Duguid JR, De La Paz R, DeGroot J (1986) Magnetic resonance imaging of the midbrain in Parkinson's disease. Ann Neurol 20: 744-747
14. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E, Przedborski S, Fahn S (1993) Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 33: 518-527
15. Feamley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301
16. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES (1987) Cerebral metabolism of 6-[18F]Fluoro-L-3 ,4-dihydroxyphenylalanine in the primate. J Neurochem 48: 1077-1082
17. Foster NL, Oilman S, Berent S, Morin EM, Brown MB, Koeppe RA (1988) Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 24: 399-406
18. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34: 423-431
19. Giminez-Roldan S, Mateo D, Benito C, Grandas F, Perez-Gilabert Y (1994) Progressive supranuclear palsy and corticobasal ganglionic degeneration: differentiation by clinical features and neuroimaging techniques. J Neural Transm Suppl 42:79-90
20. Goffinet AM, De Voider AG, Gillain C, Rectem D, Bol A, Michel C, Cogneau M, Labar D, Laterre C (1989) Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol 25: 131-139
21. 11C]RTI-32 PET studies of the dopamine transporter in early dopanaive Parkinson's disease: implications for the symptomatic threshold. Neurology 48: 1578-1583
22. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyk B, Zanzi I, Eidelberg D (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123 beta-CIT-FP/SPECT and fluorine-18 FDOPA/PET. J Nucl Med 37: 1760-1765
23. Kilbourn MR, Lee LC, Jewett DM, Vander Borght TM, Koeppe RA, Frey KA (1995) In vitro and in vivo binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. J Cereb Blood Flow Metab 15 (Supp 1):S650
24. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 318:876-880
25. Konagaya M, Konagaya Y, Iida M (1994) Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 57: 1528-1531
26. Leenders KL, Frackowiak RS, Lees AJ (1988) Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 111 :615-630
27. Leenders KL, Palmer A, Turton D, Herold S, Frackowiak RSJ, Jones T (1986) In vivo measurement of the brain dopaminergic system in man using PET. Neuroradiology 698:253-262
28. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD (1986) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853-860
29. Leenders KL, Palmer A, Turton D, Quinn N, Firnau G, Garnett S, Nahmias C, Jones T, Marsden CD (1986) DOPA uptake and dopamine receptor binding visualized in the human brain in vivo. In: Fahn S, Marsden CD, Jenner P, Teychenne P (eds) Recent developments in Parkinson's disease. Raven Press, New York, pp 103-113
30. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sagar H, Jones T, Marsden CD, Frackowiak RSJ (1990) The nigro-striatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47: 1290-1298
31. Marek KL, Innis R, Seibyl J (1999) β-CIT/SPECT assessment of determinants of variability in progression of Parkinson's disease. Neurology 52 (Supp 2):A91-A92
32. Marek KL, Seibyl J, Fussell B, Cellar J, Smith E, Innis R (1997)1231 β-CIT: Assessment of progression in Parkinson's disease. Neurology 48 (Supp 2): A 207
33. Marek K, Seibyl JP, Zoghhi SS, Zeaponce Y, Baldwin RM, Fussell B, Charney DS, Vandyck C, Hoffer PB, Innis RB (1996) [I-123] beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinsons disease. Neurology 46: 231-237
34. Martin WRW, Stoessl AJ, Adam MJ, et al. (1986) Positron emission tomography in Parkinson's disease: glucose and dopa metabolism. Adv Neurol 45: 95-98
35. 123I]β-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 25: 1270-1276
36. 18F]dopa PET. J Neurol Neurosurg Psychiatry 64: 314-319
37. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59: 597-600
38. 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 119:585-591
39. Nahmias C, Garnett ES, Firnau G, Lang A (1985) Striatal dopamine distribution in Parkinsonian patients during life. J Neurol Sci 69:223-230
40. 18F]Dopa PET study. Neurology 52 (Supp 2): A91
41. 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 54:898-904
42. Otsuka M, Ichiya Y, Kuwabara Y, Miyake Y, Tahara T, Masuda K. Hosokawa S, Goto I, Kato M, Ichimiya A, Suetsugu M (1989) Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy. Ann Nucl Med 3:111-118
43. Pastakia B, Polinsky R, Di Chiro G, Simmons JT, Brown R, Wener L (1986) Multiple system atrophy (Shy-Drager Syndrome): MR imaging. Radiology 159:499-502
44. Piccini P, Burn DJ, Ceravalo R, Maraganore DM, Brooks DJ (1999) The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45: 577-582
45. 18F-dopa PET study. Ann Neurol 41: 222-229
46. Raff U, Hutchinson M (1999) MRI reveals structural changes in the substantia nigra in Parkinson's disease. Neurology 52 (Supp 2): A90
47. 18F-dopa PET in early and advanced Parkinson's disease. Mov Disord 11 (Supp 1):147
48. 18F-dopa PET study. Brain (In press)
49. Rinne JO, Rummukainen J, Lie M, Paljarvi L, Rinne UK (1989) Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26:47-50
50. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S (1987) Study of movement disorders and brain iron by MR. Am J Roentgenol 149:365-379
51. Salmon BP, Brooks DJ, Leenders KL, Turton DR, Hume SP, Cremer JE, Jones T, Frackowiak RSJ (1990) A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab 10: 307-316
52. Savoiardo M, Girotti F, Strada L, Ciceri E (1994) Magnetic resonance imaging in progressive supranuelear palsy and other parkinsonian disorders. J Neural Transm Suppl 42:93-110
53. Savoiardo M, Strada L, Girotti F. Zimmerman RA, Grisoli M, Testa D, Petrillo R (1990) Olivipontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy. Radiology 174: 693-696
54. 18F]Dopa PET data. Arch Neurol 51:237-243
55. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de-novo parkinsonism. Neurology 42:55-561
56. 123-I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 13:16-19
57. Schwarz J, Tatsch K, Linke R, Pogarell O, Mozley D, Kung HF (1997) Measuring the decline of dopamine transporter binding in patients with Parkinson's disease using 1231-IPT and SPECT. Neurology 48 (Supp 2):A208
58. 123I-IPT and SPECT in patients with Parkinson's disease and controls. Mov Disord 11 (Supp 1): 104
59. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38:589-598
60. 123I]β-CIT for SPECT imaging of dopamine transporters in Parkinson's disease. Mov Disord 11 (Supp 1):110
61. 2 receptors in Parkinson's disease and striato-nigral degeneration determined by positron emission tomography. In: Nagatsu T, Fisher A, Yoshida M (eds) Basic, clinical, and therapeutic advances of Alzheimer's and Parkinson's diseases. Vol 2. Plenum Press, New York, pp 107-110
62. 1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56:467-472
63. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34:324-330
64. Tedroff J, Aquilonius S-M, Hartvig P, Lundqvist H, Gee AG, Uhlin J, Lângstrôm B (1988) Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11 C-nomifensine and positron emission to-mography: the effects of age and Parkinson's disease. Acta Neurol Scand 77: 192-201
65. Tedroff J, Aquilonius S-M, Laihinen A, Rinne U, Hartvig P, Andersson J, Lundqvist H, Haarparanta M, Solin O, Antoni G, Gee AD, Ulin J, Lângstrom B (1990) Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 81:24-30
66. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36:759-764
67. Yagishita A, Oda M (1996) Progressive supranuclear palsy: MRI and pathological findings. Neuroradiology 38:S60-S66